此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 Mirivadelgat 在 PH-ILD 中的安全性和有效性的研究 (WINDWARD)

2026年9月17日 更新者:Foresee Pharmaceuticals Co., Ltd.

一项多国 2 期、随机、双盲、安慰剂对照、多剂量研究,旨在评估 Mirivadelgat(一种醛脱氢酶 2 激活剂)在伴有间质性肺病 (PH-ILD) 的肺动脉高压患者中的安全性和有效性

The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs.

Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being.

Participants will:

Take mirivadelgat or a placebo once a day for 12 weeks

Visit the clinic once every 4 weeks for checkups and tests

Receive phone calls every one or two weeks to check on how things are going

研究概览

详细说明

The study is a phase 2, multinational, double-blind, 3-arm study to evaluate the safety and efficacy of mirivadelgat, an aldehyde dehydrogenase 2 activator, in adult subjects (aged 18 to 85 years) with PH-ILD. Participants must have a confirmed diagnosis of ILD as defined by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and/or Latin American Thoracic Society (ALAT) guidelines (Raghu, 2018). The diagnosis is based on a HRCT either performed at screening or within 180 days prior to screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy)) and an RHC performed at screening.

To be eligible for the study, a participant must be willing to undergo a Right Heart Catheterization (RHC) during screening and at the Week 12 Visit (at the end of study treatment). Participants on chronic treatment for underlying pulmonary diseases must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days prior to screening.

The study will enroll approximately 126 participants, assuming a drop-out rate of 20%, to obtain 99 evaluable participants (33 evaluable subjects in each cohort).

Study visits will include a Screening Visit; Visit 2 (Study Day 1); Weeks 2, 3, 4, 6, 8,10, and 12 Visits (+/ 3 days); and a safety Follow-up Visit (+/ 3 days) after the Week 12 Visit. Visits on Weeks 2, 3, 6, and 10 will be conducted by phone calls.

研究类型

介入性

注册 (估计的)

126

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Kaohsiung City、台湾、813
        • 终止
        • Kaohsiung Veterans General Hospital
      • Taipei、台湾、104
        • 招聘中
        • MacKay Memorial Hospital
        • 首席研究员:
          • Yih-Jer Wu, MD
        • 接触:
    • Taiwan
      • Hualien City、Taiwan、台湾、970
        • 招聘中
        • Hualien Tzu Chi Hospital
        • 首席研究员:
          • Wei-Hsin Liu, M.D.
        • 接触:
      • Kaohsiung City、Taiwan、台湾
        • 终止
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung、Taiwan、台湾、407219
        • 招聘中
        • Taichung Veterans General Hospital
        • 首席研究员:
          • Pin-Kuei Fu, M.D.
        • 接触:
      • Tainan、Taiwan、台湾、704
        • 终止
        • National Cheng Kung University Hospital
      • Taipei、Taiwan、台湾、11217
        • 招聘中
        • Taipei Veterans General Hospital
        • 接触:
        • 首席研究员:
          • Shih-Hsien Sung, M.D.
        • 接触:
      • Taipei、Taiwan、台湾、100225
        • 招聘中
        • National Taiwan University Hospital
        • 首席研究员:
          • Ping-Hung Kuo, M.D.
        • 接触:
      • Taoyuan City、Taiwan、台湾
        • 招聘中
        • Chang Gung Memorial Hospital - Linkou Branch
        • 首席研究员:
          • Wan-Jing Ho, M.D.
        • 接触:
      • Banja Luka、波斯尼亚和黑塞哥维那、78000
        • 尚未招聘
        • University Clinical Centre of the Republic of Srpska
      • Sarajevo、波斯尼亚和黑塞哥维那、71000
        • 尚未招聘
        • Clinical Center of the University of Sarajevo

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 85年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. A clinical diagnosis of PH-ILD.

  2. Participant voluntarily gives informed consent.

  3. Male or female participants aged between 18 and 85 years at the time of signing informed consent.

  4. Participants must agree to practice protocol-defined birth control during the study period, unless they meet criteria for not being of childbearing potential.

    • Male participants with female partners of childbearing potential must practice protocol- defined birth control for the duration of treatment and at least 96 hours after discontinuing the IP.

    • Female participants of childbearing of potential (including those <1-year post-menopausal) must practice protocol-defined birth control during the conduct of the study and for 30 days after the last dose of IP (males only during exposure to IP).

    • Female participants not of childbearing potential (as defined below) are eligible for enrolment without contraception requirements:

      1. Post-menopausal women (at least 12 months with no menses without an alternative medical cause); in women <45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR
      2. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR
      3. Have a congenital or acquired condition that prevents childbearing.
  5. The participant has a confirmed diagnosis of any form of interstitial lung disease based on high-resolution computed tomography (HRCT) of the chest within 180 days prior to screening or at screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy). The participant can have other findings (e.g., emphysema) if this is not the predominant feature on the scan.

  6. Participants have undergone RHC during the screening period with the following documented parameters:

    • Pulmonary vascular resistance (PVR) ≥4 Wood units and
    • Pulmonary capillary wedge pressure (PCWP) of ≤12 mmHg [if PVR ≥4 Wood units to <6.25 Wood units] or PCWP ≤15 mmHg [if PVR ≥6.25 Wood units] Note: If a reliable PCWP cannot be obtained, left ventricular end-diastolic pressure (LVEDP), measured via left heart catheterization (LHC), will be acceptable, with the same numerical thresholds as the PCWP criterion: LVEDP of ≤12 mmHg [if PVR ≥4 to <6.25 Wood units], or LVEDP ≤15 mmHg
    • A mean pulmonary arterial pressure (PAP) of >20 mmHg.
  7. Participants must have a 6-minute walk distance ≥100 meters and ≤500 meters at the Screening Visit (Visit 1).

  8. Participants agree to a repeat RHC, Chest CT, and MRI prior to study completion.

  9. Participants on chronic treatment for underlying lung disease (i.e., nintedanib or pirfenidone or immunosuppressive agents etc.) must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days.

  10. Participants on supportive medications (e.g., inhalers for asthma) must be on stable doses for ≥30 days prior to screening.

  11. In the Investigator's opinion, the participant must be able to consent for themselves and communicate with local staff using interpreters if necessary. Participants must agree to attend all study visits and be contactable through a cellular device or landline.

  12. Participants must have clinical laboratory values within normal ranges or <1.5 times the upper limit of normal (ULN) as specified by the testing laboratory.

  13. Participants must meet the following requirements for the pulmonary function test (PFT) at screening:

    • Forced vital capacity (FVC) <90% of predicted
    • Diffusion capacity of carbon monoxide (DLCO) <70% of predicted, or <70% of predicted corrected for hemoglobin (Hb), if correction is required. (Correction applies if Hb value is ≥25% and ≤90% of normal.) Note: DLCO must be determined locally at screening, using American Thoracic Society (ATS) standards. Hemoglobin correction should reference ATS normal values: Men = 14.6 g/dL, Women = 13.4 g/dL.
  14. Negative serology test for hepatitis B surface antigen and hepatitis C antibody at Screening Visit.

Exclusion criteria:

Medical Conditions

  1. Participant has another concomitant diagnosis of pulmonary hypertension not otherwise considered to be PH-ILD. This would include and is not limited to the concomitant presence of thromboembolic disease, untreated/inadequately treated obstructive sleep apnea, human immunodeficiency virus (HIV), methamphetamine or anorexigenic drug use, and other conditions of the WHO Group 1, 2, 4, and 5 classifications.

  2. Participant has evidence of clinically significant left-sided heart disease within 6 months of screening as defined by:

    • Left ventricular ejection fraction <40% as assessed by echocardiography.
    • More than mild left-sided valvulopathy (e.g., worse than mild mitral stenosis or regurgitation and worse than mild aortic stenosis or regurgitation).
    • LVEDP or PCWP >15 mmHg (or >12 mmHg if PVR ≥4 to 6.25 Wood units).
  3. Participants must NOT have 3 or more of the following left ventricular disease/dysfunction risk factors at screening:

    • Body mass index (BMI) ≥30 kg/m2.

    • Uncontrolled diabetes, as evidenced by HbA1C >9.5%, or urine glycosuria >1.0 g/dl, or presence of diabetic ketoacidosis.

    • History of significant coronary disease within 6 months of screening as demonstrated by any of the following:

      1. History of myocardial infarction or acute coronary syndrome (unstable angina), or
      2. Percutaneous coronary intervention or percutaneous transluminal angioplasty, or previous coronary artery bypass graft, or
      3. Evidence of coronary artery disease (>50% stenosis in at least one major coronary artery) or abnormal nuclear stress test.
  4. The participant is receiving ≥10 L/min of oxygen supplementation by any mode of delivery at rest.

  5. The participant has received any PH-approved therapy, including soluble guanylate cyclase inhibitors, endothelin receptor antagonists, or parenteral or oral prostacyclin therapy (excluding vasoreactivity testing) within 60 days of randomization or 5 half-lives. Use of phosphodiesterase type 5 inhibitors and inhaled prostacyclin (e.g., inhaled treprostinil) on stable doses for ≥30 days prior to screening will be allowed irrespective of local approval (as per ESC/ERS 2022).

  6. Use of any inhibitors and inducers of cytochrome P450 3A4 (CYP3A4) (e.g., boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib, nefazodone, nelfinavir, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort). For a comprehensive list, please refer to the FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems (FDA 2025).

  7. Recent exacerbation of underlying lung disease or active pulmonary/upper respiratory tract infection within 4 weeks of randomization.

  8. Any current active malignancy (this does not include localized cancers such as basal or squamous cell carcinoma of the skin). Any history of malignancy that is likely to result in mortality or require significant medical or surgical intervention within the following year.

  9. Chronic kidney disease Stage IV or greater (i.e., eGFR ˂30 mL/min/1.73m2) or evidence of acute kidney injury.

  10. The participant has a history of congenital heart disease, irrespective of any prior treatment or surgical intervention

  11. Use of tobacco, e-cigarette, nicotine, or marijuana products or a significant history of drug or alcohol abuse within 6 months of screening.

  12. Acute pulmonary embolism within 90 days of screening.

  13. Participation in pulmonary rehabilitation within 90 days of screening. However, participants who were on stable pulmonary rehabilitation for more than 90 days before screening may be considered for the study, provided they meet all other inclusion criteria.

  14. Prior or concurrent use of any investigational drug/device/therapy or participation in any investigational study with therapeutic intent within 30 days or 5 half-lives, whichever is longer, before the first dose of the IP.

  15. BMI ≥40 kg/m2.

  16. Uncontrolled hypertension as evidenced by systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg during the screening period. Participants who fail screening due to high blood pressure can be re-screened once after their antihypertensive medications have been adjusted and their doses have been stable for at least 4 weeks.

  17. Concomitant disease that confers a life expectancy of <6 months at screening.

  18. The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with the study procedures and treatment of addiction or any other relevant medical or psychiatric conditions.

  19. High likelihood of lung transplantation (in the opinion of the Investigator) within 4 months after randomization.

  20. History of liver dysfunction, including participants with moderate (Child-Pugh B) or severe (Child-Pugh C) impairment or disordered coagulation.

  21. Female participants who are pregnant or breastfeeding.

  22. Worse than mild untreated sleep apnea (5-14.9 events/hour). Treated sleep apnea is permitted.

  23. Participants with a prior diagnosis of connective tissue diseases, e.g., systemic sclerosis (scleroderma), systemic lupus erythematosus, Sjogren's disease, polymyositis/dermatomyositis/antisynthetase syndrome, or rheumatoid arthritis.

    Other Exclusions

  24. History of allergic or anaphylactic reaction to mirivadelgat or to any component of the excipient.

  25. Previous exposure to mirivadelgat.

    Diagnostic Assessments

  26. The following laboratory parameters are excluded:

    • Hemoglobin <10 g/dL (100 g/L).
    • White blood cells (WBC) <3000/µL (<3000/mm3).
    • Platelet count <70,000/µL (70,000/mm3).
    • Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or evidence of acute kidney injury.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:150 mg mirivadelgat

150 mg mirivadelgat once daily

Selective aldehyde dehydrogenase 2 (ALDH2) activator

其他名称:
  • FP-045
实验性的:300 mg mirivadelgat

300 mg mirivadelgat once daily

Selective aldehyde dehydrogenase 2 (ALDH2) activator

其他名称:
  • FP-045
安慰剂比较:placebo

placebo once daily

placebo

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pulmonary Vascular Resistance (PVR)
大体时间:12 weeks

The mean change from baseline to Week 12 in PVR assessed by right heart catheterization (RHC) for mirivadelgat vs. placebo.

12 weeks

次要结果测量

结果测量
措施说明
大体时间
6-minute walk distance
大体时间:12 weeks

The mean change from baseline to Week 12 in the 6-minute walk distance

12 weeks
Time to clinical deterioration from baseline to Week 12 for any of the following ADJUDICATED clinical events
大体时间:12 weeks
  • Death (all-cause mortality).
  • Hospital admission greater than 24 hours due to worsening of pulmonary hypertension.
  • Worsening of pulmonary hypertension resulting in the need for lung transplant or balloon atrial septostomy.
  • Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary hypertension-specific therapies, or need for an increase of diuretics for more than 4 weeks due to worsening of pulmonary hypertension.
  • Disease progression.
  • A decrease of more than 15% from the baseline in the 6-minute walk distance test combined with World Health Organization (WHO) functional class III or IV symptoms at 2 consecutive visits separated by at least 7 days.
12 weeks
Long-term prognostic risk factors
大体时间:12 weeks

The mean change from baseline to Week 12 of long-term prognostic risk factors of plasma/serum N-terminal pro-brain natriuretic peptide (NT-ProBNP), C-terminal procollagen I (PICP), N-terminal procollagen I (NICP or PINP), and N-terminal procollagen III (NIIICP or PIIINP).

12 weeks
Patient-reported outcome measures (PROMS): (SF)-36v2
大体时间:12 weeks

The change from baseline to Week 12 in the Short Form (SF)-36v2 Health Survey with Scale 0 to 100 (mean is 50), 0 is worst, 100 is best

12 weeks
Patient-reported outcome measures (PROMS): WIQ
大体时间:12 weeks

The change from baseline to Week 12 in the Walking Impairment Questionnaire (WIQ) with percentage scale ranging from 0% (worst) to 100% (best)

12 weeks
Patient-reported outcome measures (PROMS): PAH-SYMPACT
大体时间:12 weeks

The change from baseline to Week 12 in the Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire (PAH-SYMPACT) with each point scored from 0 (best) to 4 (worst)

12 weeks

其他结果措施

结果测量
措施说明
大体时间
Inflammatory markers
大体时间:12 weeks

The mean change in concentration of inflammatory markers interleukin-6 (IL-6), high-sensitivity C-reactive protein (HS-CRP), and tumor necrosis factor- α (TNF-α) from baseline to Week 12.

12 weeks
Change in Biomarkers
大体时间:Week 12

The mean change in biomarkers related to fibrogenesis, inflammation, tissue destruction, and epithelial damage, including but not limited to PRO-C3, PRO-C6, C1M, C3M, C6M, C4Malph3, VICM, and CC16-HNE, from baseline to Week 12

Week 12
Cardiac MRI fibrosis score
大体时间:12 weeks

The mean change in cardiac MRI fibrosis score assessed by cardiac MRI gadolinium enhancement from baseline to Week 12 with a continuous variable that is not presented on a scale (only for subjects who have no contraindication to MRI procedure).

12 weeks
Quantitative ILD features
大体时间:12 weeks

The change in Quantitative ILD features [i.e., Ground glass (QGC), Lung fibrosis (QLF), and Honeycombing (QHC)] assessed by HRCT scan from baseline to Week 12.

12 weeks
Risk for intervention
大体时间:12 weeks

The Absolute Risk for intervention regarding specific events of death and stroke (CVA) (the absolute risk reduction between placebo and treatment of the composite event of death and stroke)

12 weeks
Change of right ventricle/left ventricle (RV/LV) size
大体时间:12 weeks

The mean change in transthoracic echocardiography measurement of right ventricle/left ventricle (RV/LV) size, function, and strain from baseline to Week 12.

12 weeks
Pulmonary function tests (PFTs) - FEV1
大体时间:12 weeks

The change in FEV1 from baseline to Week 12.

12 weeks
Pulmonary function tests (PFTs) - FEV1 / FVC ratio and diffusion capacity of carbon monoxide (DLCO)
大体时间:12 weeks

The change in FEV1 / FVC and DLCO from baseline to Week 12.

12 weeks
Pharmacokinetic (PK) parameters: T1/2
大体时间:12 weeks

T1/2 for mirivadelgat and its active metabolite AD-835.

12 weeks
Pharmacokinetic (PK) parameters: AUC
大体时间:12 weeks

AUC for mirivadelgat and its active metabolite AD-835.

12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 研究主任:Bassem Elmankabadi, MD、Foresee Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月1日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2024年6月12日

首先提交符合 QC 标准的

2024年6月19日

首次发布 (实际的)

2024年6月26日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • FP-045C-23-001

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅